Display options
Cite
Herman RB, Jesudason PJ, Mustafa AM, et al. Differential effects of carvedilol and atenolol on plasma noradrenaline during exercise in humans. Br J Clin Pharmacol. 2003;55(2):134-8doi: 10.1046/j.1365-2125.2003.01755.x.
Herman, R. B., Jesudason, P. J., Mustafa, A. M., Husain, R., Choy, A. M., & Lang, C. C. (2003). Differential effects of carvedilol and atenolol on plasma noradrenaline during exercise in humans. British journal of clinical pharmacology, 55(2), 134-8. https://doi.org/10.1046/j.1365-2125.2003.01755.x
Herman, Rahmatina B, et al. "Differential effects of carvedilol and atenolol on plasma noradrenaline during exercise in humans." British journal of clinical pharmacology vol. 55,2 (2003): 134-8. doi: https://doi.org/10.1046/j.1365-2125.2003.01755.x
Herman RB, Jesudason PJ, Mustafa AM, Husain R, Choy AM, Lang CC. Differential effects of carvedilol and atenolol on plasma noradrenaline during exercise in humans. Br J Clin Pharmacol. 2003 Feb;55(2):134-8. doi: 10.1046/j.1365-2125.2003.01755.x. PMID: 12580984; PMCID: PMC1894730.
Copy Download .nbib Format: NLM
Share it on

Br J Clin Pharmacol. 2003 Feb;55(2):134-8. doi: 10.1046/j.1365-2125.2003.01755.x.

Differential effects of carvedilol and atenolol on plasma noradrenaline during exercise in humans.

British journal of clinical pharmacology

Rahmatina B Herman, Peter J Jesudason, Ali M Mustafa, Ruby Husain, Anna Maria J Choy, Chim C Lang

Affiliations

  1. Faculty of Medicine, University of Andalas, Indonesia.

PMID: 12580984 PMCID: PMC1894730 DOI: 10.1046/j.1365-2125.2003.01755.x

Abstract

AIMS: Evidence of long-term beneficial effects of beta-blockers on mortality and morbidity in patients with heart failure has been demonstrated in recent randomized trials. However, not all beta-blockers are identical. Carvedilol, a nonselective beta- and alpha-adrenergic blocker, can potentially blunt the release of noradrenaline by blocking presynaptic beta2-adrenergic receptors. To test this hypothesis, we have compared the effects of carvedilol and atenolol on plasma noradrenaline during exercise in healthy young volunteers.

METHODS: This study investigated the differential effects of 2 weeks pretreatment with carvedilol 25 mg day(-1) and atenolol 50 mg day(-1) on plasma noradrenaline at rest and during exercise on a treadmill in a double-blind randomized crossover study, involving 12 healthy male volunteers (mean age 21.6 +/- 0.3 years).

RESULTS: Haemodynamic parameters at rest and during exercise were not significantly different in either carvedilol or atenolol pretreatment groups. However, carvedilol pretreatment significantly blunted the increase in plasma noradrenaline during exercise [393.8 +/- 51.7 pg ml(-1) (pretreatment) to 259.7 +/- 21.2 pg ml(-1) (post-treatment)], when compared with atenolol [340.4 +/- 54.6 pg ml(-1) (pretreatment) to 396.2 +/- 32.0 pg ml(-1) (post-treatment)]. The difference between carvedilol and atenolol (95% confidence interval) was -145.2, -351.0, P < 0.05.

CONCLUSIONS: We have demonstrated that carvedilol but not atenolol significantly blunted the increase in plasma noradrenaline during exercise. These findings may suggest a sympathoinhibitory effect of carvedilol that may enhance its ability to attenuate the cardiotoxicity associated with adrenergic stimulation in patients with heart failure.

References

  1. Circulation. 2002 May 21;105(20):2429-34 - PubMed
  2. Circulation. 2001 Oct 30;104(18):2194-9 - PubMed
  3. Prog Cardiovasc Dis. 1976 May-Jun;18(6):421-44 - PubMed
  4. Am J Cardiol. 1982 Apr 1;49(5):1152-6 - PubMed
  5. Am J Cardiol. 1982 May;49(7):1659-66 - PubMed
  6. Br J Clin Pharmacol. 1984 Oct;18(4):573-9 - PubMed
  7. Circulation. 1986 May;73(5):913-9 - PubMed
  8. J Cardiovasc Pharmacol. 1987 Mar;9(3):317-27 - PubMed
  9. J Cardiovasc Pharmacol. 1989 Apr;13(4):572-9 - PubMed
  10. Circ Res. 1990 Jun;66(6):1610-23 - PubMed
  11. Eur Heart J. 1991 Aug;12 Suppl C:21-8 - PubMed
  12. Am J Cardiol. 1992 Feb 15;69(5):523-31 - PubMed
  13. J Cardiovasc Pharmacol. 1992;19 Suppl 1:S68-80 - PubMed
  14. J Cardiovasc Pharmacol. 1992;19 Suppl 1:S82-5 - PubMed
  15. J Am Coll Cardiol. 1993 Oct;22(4 Suppl A):56A-60A - PubMed
  16. Gen Pharmacol. 1993 Jul;24(4):785-96 - PubMed
  17. Am J Hypertens. 1994 Feb;7(2):129-36 - PubMed
  18. Prog Cardiovasc Dis. 1995 May-Jun;37(6):397-414 - PubMed
  19. Eur Heart J. 1996 Apr;17 Suppl B:8-16 - PubMed
  20. Eur J Clin Pharmacol. 1996;50(6):483-9 - PubMed
  21. Circulation. 1996 Dec 1;94(11):2817-25 - PubMed
  22. Circulation. 1997 Jul 1;96(1):238-45 - PubMed
  23. Circulation. 1999 May 25;99(20):2645-51 - PubMed
  24. N Engl J Med. 1962 Sep 27;267:650-4 - PubMed
  25. J Am Coll Cardiol. 1999 Nov 1;34(5):1522-8 - PubMed
  26. Biochem Pharmacol. 2000 Apr 15;59(8):1007-13 - PubMed
  27. Circulation. 2000 Aug 1;102(5):546-51 - PubMed
  28. N Engl J Med. 2001 May 31;344(22):1659-67 - PubMed
  29. Curr Opin Cardiol. 2001 May;16(3):180-5 - PubMed
  30. Ann N Y Acad Sci. 2001 Jun;940:500-13 - PubMed
  31. Am Heart J. 1973 Apr;85(4):546-62 - PubMed

Substances

MeSH terms

Publication Types